Targovax logoTargovax logo

  • About
    About
    Close
      • About Targovax
      • Management Team
      • Board of Directors
      • Careers
  • Technology
    Technology
    Close
      • ONCOS – Oncolyctic Virus
      • Intellectual Property Rights
      • Publications
  • Pipeline
    Pipeline
    Close
      • Our pipeline
      • Development Program
        • Melanoma
        • Mesothelioma
        • Next generation viruses
  • Partnering
  • Investors & Media
    Investors & Media
    Close
      • Our strategy
      • Press releases
      • Financial Reports
      • Presentations
      • Prospectus
      • Debt
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Events
      • Contact
      • Subscribe
  • Governance
    Governance
    Close
      • Corporate Governance Policy
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
  • Contacts
    Contacts
    Close
      • Offices
      • Investors & Media
    • About
      • About Targovax
      • Management Team
      • Board of Directors
      • Collaborations
      • Careers
    • Technology
      • ONCOS – Oncolyctic Virus
      • Intellectual Property Rights
      • Publications
    • Pipeline
      • Our pipeline
      • Development program
    • Partnering
      • TG Mutant RAS neoantigen vaccine – Available for partnering
    • Investors & Media
      • Our strategy
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Financial Reports
      • Press releases
      • Presentations
      • Prospectus
      • Debt
      • Events
      • Subscribe
      • Contact
    • Governance
      • Corporate Governance Report
      • Corporate Social Responsibility Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
    • Contacts
      • Offices
      • Investors & Media

    Annual General Meeting 2021

    March 17, 2021

    The annual general meeting of Targovax ASA (the “Company”) was held on 17 March 2021 at 10:00 hours (CET), at the Company’s offices in Vollsveien 19, 1366 Lysaker in the municipality of Bærum.

     

    Documents

    • Targovax AGM 2021 notice
      February 17, 2021
    • Targovax – Recommendations from the Nomination Committee
      February 17, 2021
    • Targovax remuneration principles 2021
      February 24, 2021
    • Minutes from AGM 2021
    IR contact
    Dr Lubor Gaal
    Dr Lubor Gaal
    Chief Financial Officer
    lubor.gaal@targovax.com
    (+34) 683 343 811
    Renate Birkeli
    Renate Birkeli
    Investor Relations
    renate.birkeli@targovax.com
    (+47) 922 61 624

    Annual Report 2021

    Published March 9, 2022.

    • Annual Report 2021
    Archive financial reports

    Subscribe

    Read more about our Protection of your personal data.
    • PRINT
    • STAY CONNECTED
    • Cookies
    • Privacy policy